CEL-SCI Corporation news

   Watch this stock
Showing stories 11 - 20 of about 88   

Articles published

CVM 1.96 +0.06 (3.16%)
price chart
CEL-SCI Corp (CVM) Responds to FDA for Phase 3 Head and Neck Cancer Trial
CEL-SCI Corporation (NYSE: CVM) today announced that it has responded to the U.S. Food and Drug Administration's (FDA) most recent communication from May 2017 about the clinical hold imposed on the Company's Phase 3 head and neck cancer study with ...
CEL-SCI Extends the Expiration Date of Series DD Warrants Issued in December ...  Business Wire (press release)
CEL-SCI submits FDA response for its Phase 3 head and neck cancer trial  Seeking Alpha
CEL-SCI Announces Update on Arbitration against Former Clinical Research ...
Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving ...
CEL-SCI Announces Update on Ongoing Arbitration against Former Clinical ...
On October 3, 2017, Lake Whillans Litigation Funding and CEL-SCI agreed to give an incentive to the law firm, Wilk Auslander, which is handling the case for CEL-SCI against the former CRO. Pursuant to this new arrangement, Lake Whillans has agreed to ...
CEL-SCI to Present at the 19th Annual Rodman & Renshaw Global Investment ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM), today announced Geert Kersten, Chief Executive Officer, will be presenting at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C.
Is CEL-SCI Corporation (NYSEMKT:CVM) About To Get An FDA Resolution?
CEL-SCI Corporation (NYSEMKT:CVM) has had a noteworthy run year to date. The company started out 2017 at around $0.07 a share, and has since gained to trade above $0.11 - a 60% gain across the period.
The Saga Of CEL-SCI Corporation (NYSEMKT:CVM)'S Bleak Clinical Trials  Journal Transcript
CEL-SCI Announces $1.5 Million NIH SBIR Grant to Support Development of ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) announced today that it has been awarded a new Phase II Small Business Innovation Research (SBIR) grant by the National Institute of Arthritis and Musculoskeletal and Skin Diseases ...
US FDA Removes Clinical Hold on CEL-SCI's Phase 3 Head & Neck Cancer Trial
Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving ...
CEL-SCI Corporation (CVM) Stock: Gaining Big On FDA News  CNA Finance (press release)
CEL-SCI Corporation (NYSEMKT:CVM) Is Finally Getting Some Reprieve  Insider Financial
Guru Analysis Of CEL-SCI Corporation (CVM)
CEL-SCI Corporation (NYSE:CVM) enjoyed a 51.37% run-up in share price since hitting record low of $1.46. The stock managed 11.06% rise and now stands at $2.21 as of 01/11/2018.
The Factor Everyone Ignores: CEL-SCI Corporation (CVM), Actinium ...  StandardOracle
Analyst Opinion Summary: BioLine Rx Ltd (BLRX), CEL-SCI Corporation (CVM)  Analyst Journal
CEL-SCI Granted European Patent for Multikine's Mechanism of Action in Making ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) announced today that the European Patent Office has issued a new patent to CEL-SCI for its lead investigational immunotherapy, Multikine* (Leukocyte Interleukin, Injection), which ...
The Fundamental Case for and Against CEL-SCI Corporation (CVM)  StockNewsGazette
FDA places CEL-SCI's late-stage Multikine study in head and neck cancer on ...
The FDA has notified CEL-SCI (NYSEMKT:CVM) that its Phase 3 clinical trial assessing Multikine (Leukocyte Interleukin, Injection) for the treatment of head and neck cancer is on full clinical hold, meaning that all dosing must cease immediately.
CEL-SCI Corporation (CVM) Stock: Takes A Dive On FDA Clinical Hold  CNA Finance (press release)